JOHNSON & JOHNSON (JNJ) Form 10-Q — Jul 23, 2026
Sales for the six months ended June 28, 2026, increased 8.2% to $49.4 billion, driven by operational growth of 6.0% and a positive currency impact. Second quarter sales rose 6.6% to $25.3 billion, with Innovative Medicine sales up 9.4% year-over-year primarily due to strong performance in Oncology, partially offset by the impact of STELARA biosimilars. Net earnings for the six months decreased to $10.8 billion from $16.5 billion in the prior year, largely due to the absence of a $7.0 billion talc reserve reversal recorded in 2025 and new litigation charges.
Key figures
- Eps
- 4.41
- Revenue
- 49372
- Net Income
- 10769
- Revenue Yoy
- 8.2%
- Cash Position
- 20422
- Stelara biosimilar impact 6m
- -5.0%
- Firefly bio acquisition value
- 1000
- Orthopaedics separation costs 6m
- 400
Price after filing
Close on the filing date to close N calendar days later (from $259.27). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.